152
Participants
Start Date
March 31, 2020
Primary Completion Date
August 20, 2020
Study Completion Date
August 20, 2020
Discontinuation of ARB/ACEI
The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.
Continuation of ARB/ACEI
The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).
University of Pennsylvania Health System, Philadelphia
Collaborators (2)
Jordana B. Cohen, MD, MSCE
UNKNOWN
Hanff, Thomas C., M.D., MPH
INDIV
University of Arizona
OTHER
Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud
OTHER
Hospital Nacional Edgardo Rebagliati Martins
OTHER
Hospital Español de Mendoza
OTHER
Stanford University
OTHER
Ottawa Hospital Research Institute
OTHER
Hospital Civil de Guadalajara
OTHER
Universidad Catolica Argentina
OTHER
Caja Nacional de Salud
OTHER
Departamento de Medicina, Hospital Alberto Barton Thompson, Callao, Peru
OTHER
Karolinska Institutet
OTHER
University of Miami
OTHER
Division of Cardiology, Department of Medicine, Hospital Español, Buenos Aires, Argentina
OTHER
University of Michigan
OTHER
Jesse Chittams, MS
UNKNOWN
Duke University
OTHER
Vasquez, Charles R., M.D.
INDIV
University of Pennsylvania
OTHER